【摘要】 目的:检测新型有机硒化合物双硒唑烷-1(Ethaselen-1,Eb1)的动物体内免疫调节作用。方法:建立Lew-is肺癌(Lew is lung cancer,LLC)皮下移植瘤C57/BL鼠动物模型,选取25.0 mg/kg和12.5 mg/kg两个剂量的Eb1作为实验药物,以左旋咪唑(levam isole,LMS)2.0 mg/kg作为阳性对照,以溶剂5 g/L羧甲基纤维素钠溶液为阴性对照,于接种肿瘤后第2天开始向C57/BL鼠腹腔连续注射7 d药物,探讨Eb1对正常及肿瘤鼠的相对脾重、脾淋巴细胞转化活性、自然杀伤(natural k iller,NK)细胞活性、淋巴因子-激活杀伤(lymphok ine-activated k iller,LAK)细胞活性及淋巴细胞CD4+,CD8+亚群阳性细胞百分数的影响。结果:高剂量Eb1能够使正常鼠和肿瘤鼠的相对脾重增加150.59%和122.55%,脾淋巴细胞转化活性增加162.25%和561.98%,NK细胞活性增加78.60%和219.42%,脾淋巴细胞CD4-CD8+亚群阳性细胞百分含量增加104.72%和105.87%,高剂量Eb1亦能使肿瘤鼠的LAK细胞活性增加195.11%,与对照组相比差异均有统计学意义(P<0.01)。结论:新型有机硒化合物Eb1在C57/BL小鼠体内具有明显的免疫调节作用。更多还原

【Abstract】 Objective: To detect the Immune regulating activity of ethaselen-1（Eb1）,a novel organoselenium compound,in C57/BL mice transplanted with Lewis lung cancer（LLC）.Methods: The LLC transplanted C57/BL mice models were established,and the mice was randomly divided into four groups,including high dose Eb1 group（25.0 mg/kg）,low dose Eb1 group（12.5 mg/kg）,positive control group（levamisole,LMS,2.0 mg/kg） and negative control group（solvent）.Intraperitoneal injections（ip.） of the four pharmaceuticals were performed once a day through the abdominal wall separately,from the second to the eighth day after cancer was transplanted.On the eleventh day,six mice of each group were killed and relative weight of spleen,transforming activity of spleen lymphocytes,NK cell activity,LAK cell activity and percentage of CD₄⁺CD₈⁺T lymphocyte were detect.Results: Compared with the control group,high dose Eb1 could obviously increase the relative weight of spleen（150.59% and 122.55%）,transforming activity of spleen lymphocytes（162.25% and 561.98%）,NK cell activity（78.60% and 219.42%） and percentage of CD₄^-/CD₈⁺ T lymphocyte（104.72% and 105.87%） in normal mice and LLC mice.Compared with the control group,high dose Eb1 could also increase LAK cell activity of LLC mice by 195.11%.Conclusion: The novel organoselenium compound Eb1 has immune regulating activity in vivo.更多还原